QuidelOrtho (NASDAQ:QDEL) Issues FY 2026 Earnings Guidance

QuidelOrtho (NASDAQ:QDEL) issued an update on its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.650-0.900 for the period, compared to the consensus earnings per share estimate of 1.850. The company issued revenue guidance of $2.5 billion-$2.6 billion, compared to the consensus revenue estimate of $2.7 billion.

Analysts Set New Price Targets

QDEL has been the topic of several research reports. Citigroup increased their target price on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Jefferies Financial Group reaffirmed a “hold” rating on shares of QuidelOrtho in a research report on Monday, June 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of QuidelOrtho in a research note on Friday, July 17th. UBS Group reissued a “neutral” rating and set a $12.00 price target on shares of QuidelOrtho in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. increased their price target on shares of QuidelOrtho from $11.00 to $12.00 and gave the stock an “underweight” rating in a research report on Wednesday, July 1st. Four equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, QuidelOrtho has an average rating of “Reduce” and a consensus target price of $13.62.

QuidelOrtho Stock Down 6.7%

Shares of NASDAQ:QDEL traded down $1.18 on Thursday, hitting $16.32. 2,729,745 shares of the company’s stock were exchanged, compared to its average volume of 1,089,908. QuidelOrtho has a 1-year low of $9.92 and a 1-year high of $35.58. The company has a market capitalization of $1.11 billion, a PE ratio of -0.92 and a beta of 0.68. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.80 and a current ratio of 1.43. The firm’s 50-day moving average is $15.77 and its 200 day moving average is $17.59.

QuidelOrtho (NASDAQ:QDEL) last issued its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.18. The business had revenue of $630.90 million for the quarter, compared to analyst estimates of $618.72 million. QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The business’s quarterly revenue was up 2.8% on a year-over-year basis. During the same quarter last year, the company earned $0.12 EPS. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Sell-side analysts predict that QuidelOrtho will post 1.87 EPS for the current year.

Trending Headlines about QuidelOrtho

Here are the key news stories impacting QuidelOrtho this week:

• Positive Sentiment: QuidelOrtho reported second-quarter adjusted earnings of $0.13 per share, well above the $0.04–$0.05 loss analysts expected and ahead of $0.12 per share a year earlier. Revenue reached $631 million, exceeding the approximately $619 million consensus estimate. QuidelOrtho Q2 earnings and revenue estimates
• Positive Sentiment: Revenue grew 3% year over year, or 2% in constant currency, led by the Labs and Point-of-Care businesses. Excluding China, revenue growth was stronger at 6% on both a reported and constant-currency basis, suggesting underlying demand remains relatively healthy. QuidelOrtho Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Options-market activity showed elevated implied volatility ahead of the earnings release, indicating that investors anticipated a potentially significant post-results move. Implied volatility for QuidelOrtho options
• Negative Sentiment: QuidelOrtho lowered its fiscal 2026 outlook to $0.65–$0.90 in EPS, versus analyst expectations near $1.85, and projected revenue of $2.5–$2.6 billion, below the roughly $2.7 billion consensus. The substantial guidance gap raises concerns about slower growth or profitability pressure during the remainder of the year. QuidelOrtho full-year 2026 guidance
• Negative Sentiment: The company continues to report a deeply negative net margin, reinforcing investor concerns that the earnings beat may not represent a durable improvement in overall profitability.

Institutional Trading of QuidelOrtho

Several institutional investors have recently modified their holdings of QDEL. Corient Private Wealth LLC acquired a new position in QuidelOrtho in the fourth quarter valued at $280,000. Schonfeld Strategic Advisors LLC increased its position in shares of QuidelOrtho by 47.1% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 15,520 shares of the company’s stock worth $443,000 after purchasing an additional 4,969 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of QuidelOrtho by 97.7% in the 4th quarter. Russell Investments Group Ltd. now owns 13,577 shares of the company’s stock valued at $392,000 after purchasing an additional 6,708 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new stake in shares of QuidelOrtho in the 3rd quarter valued at about $213,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of QuidelOrtho by 13.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,038 shares of the company’s stock valued at $561,000 after purchasing an additional 2,265 shares during the period. Hedge funds and other institutional investors own 99.00% of the company’s stock.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.